Welcome to our dedicated page for Biorestorative Therapies news (Ticker: BRTX), a resource for investors and traders seeking the latest updates and insights on Biorestorative Therapies stock.
BioRestorative Therapies, Inc. (NASDAQ: BRTX) is a regenerative medicine company focused on stem cell-based therapies and products, and its news flow reflects activity across clinical development, intellectual property, commercialization, and capital markets. The company develops therapeutic products using adult stem cell protocols, with core programs in disc and spine disease, metabolic disorders, and a commercial BioCosmeceutical platform.
News about BRTX often centers on its disc/spine program (brtxDISC™) and lead cell therapy candidate BRTX-100. Recent announcements include Fast Track designation from the U.S. Food and Drug Administration (FDA) for the BRTX-100 Phase 2 trial in chronic lumbar disc disease and the granting of a Type B meeting with the FDA to discuss a potential accelerated Biologics License Application approval pathway. Updates also cover blinded Phase 2 clinical data presented at scientific meetings and the status of enrollment and trial progress.
Another key news theme is the ThermoStem® metabolic program, where BioRestorative has reported milestones such as a Notice of Allowance from the Japanese Patent Office for its allogeneic, off-the-shelf brown adipose-derived stem cell technology designed to treat obesity and metabolic disorders. Press releases describe how this intellectual property strengthens protection for cell-based approaches that aim to generate brown adipose tissue and utilize exosomes secreted by brown adipose-derived stem cells.
Investors following BRTX news will also see coverage of the company’s BioCosmeceutical platform, including commercial developments for its cell-based secretome serum, as well as corporate events such as equity financings, stock repurchase authorizations, conference presentations, and quarterly financial results. This page aggregates these updates so readers can track BioRestorative’s clinical, commercial, and financial disclosures in one place.
BioRestorative Therapies, Inc. (NASDAQ: BRTX) announced a notice of allowance from the Japanese Patent Office for a patent linked to its ThermoStem® Program. This notice, issued on January 26, 2022, covers implantable three-dimensional scaffolds and brown adipocytes derived from human stem cells, aimed at delivering metabolically active cells for treating metabolic disorders. CEO Lance Alstodt emphasized this strengthens their global patent portfolio and highlights ThermoStem® as a viable treatment for diabetes and obesity, addressing significant unmet medical needs.
Summary not available.
BioRestorative Therapies (NASDAQ:BRTX) has appointed Robert Paccasassi as Vice President of Quality Assurance/Regulatory Compliance. With over 25 years of experience in biotech and quality systems, he will oversee quality initiatives as the company begins patient enrollment for a Phase 2 clinical trial targeting chronic lumbar disc disease. Paccasassi’s past roles include significant positions at Merck KGaA, Regeneron, Millennium, and Biogen Idec. This leadership appointment aims to enhance the company's compliance and quality control in its stem cell therapy programs.
BioRestorative Therapies (BRTX) will present a corporate overview at the H.C. Wainwright BioConnect 2022 Conference, scheduled virtually from January 10-13, 2022. CEO Lance Alstodt will lead a pre-recorded presentation available starting January 10 at 7 a.m. ET. Attendees can access the link for the presentation here. The presentation will also be archived for 30 days on the company’s website. BRTX focuses on stem cell-based treatments, including the brtxDISC™ program for spine disease and the ThermoStem® program targeting metabolic disorders.
BioRestorative Therapies announced a Phase I STTR grant of $256,000 from the NIH to evaluate the therapeutic effects of its hypoxic cultured bone marrow-derived stem cells (BRTX-100) with a novel PEG-peptide hydrogel. This collaboration with Dr. Lori Setton aims to optimize therapeutic delivery methods. Successful completion of this phase could lead to applications for Phase II funding, potentially reaching $1 million. The grant demonstrates recognition of BioRestorative's innovative approach to stem cell therapies, particularly in treating chronic lower back pain.
BioRestorative Therapies, Inc. (NASDAQ:BRTX) has signed a Master Service Agreement with PRC Clinical to manage its Phase 2 clinical trial for BRTX-100, aimed at treating chronic lumbar disc disease. PRC Clinical brings extensive experience and innovative technology to the collaboration. CEO Lance Alstodt emphasized this partnership as a significant step towards clinical development. The trial's success could advance BioRestorative's mission to develop cell-based therapeutics, as they aim for primary endpoint readouts in the near future.
BioRestorative Therapies, Inc. (NASDAQ:BRTX) announced that CEO Lance Alstodt will appear on the NewMedia Show on December 21, 2021. The show features discussions on various topics, leveraging a broad audience across social media platforms, including YouTube and LinkedIn. Alstodt expressed excitement to share the company’s 2021 achievements and future plans. BioRestorative specializes in adult stem cell-based therapies and is developing treatments for disc/spine disease and metabolic disorders, notably BRTX-100 for chronic lower back pain.
BioRestorative Therapies (NASDAQ: BRTX) recently shared a year-end update reflecting on 2021's achievements and 2022 goals. The company raised $23 million through a capital raise, enabling it to fund its Phase 2 clinical trial for BRTX-100, targeting chronic lumbar disc disease. Major milestones included uplisting to the Nasdaq, eliminating all debt, and restructuring operations. Looking ahead, BioRestorative aims to enroll patients for the BRTX-100 trial and further develop its products, particularly its ThermoStem® program.
BioRestorative Therapies, Inc. (NASDAQ:BRTX) has filed ten patent applications with the USPTO relating to its BRTX-100 program aimed at treating chronic lumbar disc disease. The patents focus on manufacturing methods for stem cells that can survive in low-oxygen environments, crucial for effective therapy. This strengthens the company's intellectual property portfolio. BioRestorative is FDA-authorized to begin a Phase 2 clinical trial for BRTX-100.
BioRestorative Therapies (NASDAQ:BRTX) has signed a letter of intent with PRC Clinical to provide startup CRO services for its BRTX-100 Phase 2 trial. This trial aims to treat chronic lumbar disc disease using an innovative stem cell therapy. PRC Clinical brings 20 years of experience in clinical trial management, enhancing patient enrollment and site monitoring. The collaboration marks a significant step towards FDA validation of their technology. CEO Lance Alstodt highlighted the importance of this partnership in updating shareholders throughout the regulatory process.